First human test for new kidney disease drug
NCT ID NCT05656040
Summary
This early-stage study tested a single injection of an experimental drug called MK-2060 in people with advanced kidney disease. The main goals were to check the drug's safety, see how long it stays in the body, and measure its effect on blood clotting. Only 14 people with stage 4 chronic kidney disease participated in this first part of the planned study.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advanced Pharma CR, LLC ( Site 0006)
Miami, Florida, 33147, United States
-
Alliance for Multispecialty Research, LLC ( Site 0002)
Knoxville, Tennessee, 37920, United States
-
Genesis Clinical Research, LLC ( Site 0004)
Tampa, Florida, 33603, United States
-
Velocity Clinical Research, New Smyrna Beach ( Site 0003)
Edgewater, Florida, 32132, United States
Conditions
Explore the condition pages connected to this study.